ASTRAZENECA PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11,928.00 GBX | -1.01% |
|
-5.71% | +12.53% |
| Sep. 13 | AstraZeneca, Daiichi Sankyo Breast Cancer Drug Trial Shows 'Substantial Clinical Activity' | MT |
| Sep. 13 | Daiichi, Astra's Enhertu shows clinical activity in brain metastases | AN |
Sales 2023 by Business Segment
Sales 2023 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
Pharmaceutical Products | ||||||||||
Biopharmaceuticals | 24.38B | 26.62B | 37.42B | 44.35B | 45.81B | |||||
Total Assets | 61.38B | 66.73B | 105B | 96.48B | 101B | |||||
Interest Expense | -780M | -738M | -776M | -917M | -1.22B | |||||
Income Tax Expense | 321M | 772M | -380M | -792M | 938M | |||||
CAPEX | -2.46B | -2.61B | -2.2B | -2.57B | -1.36B | |||||
EBT | 1.66B | 3.94B | -201M | 2.51B | 6.91B | |||||
Gross Profit | 19.46B | 21.32B | 24.98B | 31.96B | 37.54B | |||||
D&A | 2.73B | 2.83B | 4.04B | 5.18B | 4.85B | |||||
Operating Income | 2.92B | 5.16B | 1.06B | 3.76B | 8.19B | |||||
Net Income | 1.34B | 3.2B | 112M | 3.29B | 5.96B |
Geographical Revenue Distribution History
| Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
United States | 8.05B | 8.96B | 12.05B | 17.28B | 18.12B | |||||
Total Assets | 4.51B | 5.5B | 6.06B | 6.04B | 6.11B | |||||
CAPEX | -120M | -116M | -94M | - | - | |||||
EBT | 923M | 745M | 931M | 660M | 1.15B | |||||
Operating Income | 964M | 742M | 943M | 646M | 1.15B | |||||
China | 4.87B | 5.34B | 6B | 5.74B | 5.87B | |||||
Japan | 2.52B | 2.57B | 3.4B | 3.99B | 3.64B | |||||
United Kingdom | 1.82B | 1.74B | 3.24B | 3.12B | 3.37B | |||||
Total Assets | 15.3B | 17.85B | 16.62B | 16.79B | 19.62B | |||||
CAPEX | -2.26B | -1.61B | -810M | - | - | |||||
EBT | 93M | 518M | -1.48B | 272M | -577M | |||||
Operating Income | 466M | 824M | -950M | 1.12B | 665M | |||||
Other Rest of Europe | 1.29B | 1.39B | 1.95B | 2.71B | 3.11B | |||||
Germany | 704M | 937M | 1.49B | 1.9B | 2.1B | |||||
Other Asia, Africa & Australasia | 1.42B | 1.53B | 2.38B | 2.41B | 2.04B | |||||
Sweden | 834M | 1.03B | 2.32B | 1.72B | 1.7B | |||||
Total Assets | - | - | - | - | - | |||||
CAPEX | - | - | - | - | - | |||||
EBT | - | - | - | - | - | |||||
Operating Income | - | - | - | - | - | |||||
Total Assets | 18.18B | 19.74B | 48.38B | 40.67B | 40.64B | |||||
CAPEX | -386M | -505M | -26.53B | - | - | |||||
EBT | 1.01B | 2.36B | 2.68B | 2.71B | 5B | |||||
Operating Income | 1.5B | 2.84B | 3B | 2.94B | 4.88B | |||||
Other Americas | 814M | 761M | 1.2B | 1.18B | 1.68B | |||||
France | 578M | 653M | 915M | 1.11B | 1.15B | |||||
Canada | 466M | 596M | 772M | 1.17B | 967M | |||||
Spain | 359M | 398M | 578M | 738M | 847M | |||||
Italy | 396M | 431M | 577M | 735M | 813M | |||||
Australia | 266M | 282M | 547M | 571M | 390M | |||||
Intra-Group Eliminations | - | - | - | - | - | |||||
Belgium | - | - | - | - | - | |||||
Corporate | - | - | - | - | - | |||||
Total Assets | 23.38B | 23.64B | 34.3B | 32.99B | 34.75B | |||||
CAPEX | -236M | -286M | -10.81B | - | - | |||||
EBT | -474M | 297M | -2.4B | -1.14B | 1.33B | |||||
Operating Income | -8M | 758M | -1.94B | -954M | 1.5B |
- Stock Market
- Equities
- AZN Stock
- Financials AstraZeneca PLC
- Business Segments